Navigation Links
Anti-clotting agent does not improve outcomes of patients with severe pneumonia

Use of the blood clot-inhibiting medication tifacogin does not appear to improve outcomes of patients with severe community-acquired pneumonia (sCAP), according to a study conducted by researchers from North and South America, Europe, Asia and Africa. The drug had shown some potential benefit in the sCAP subgroup of an earlier trial involving sepsis patients.

The findings were published online ahead of the print edition of the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

"Administration of tifacogin showed no treatment benefit in this large population of patients with severe CAP,"said Richard Wunderink, MD, professor of pulmonary and critical care medicine at Northwestern University's Feinberg School of Medicine. "This result was consistent across a range of disease severity indices."

In the U.S., community-acquired pneumonia (CAP) is the eighthleading cause of death, with a death rate of 18.8/100,000. The number of individuals hospitalized with CAP annually is expected to increase up to 1 million in 2020, with similar trends in many other countries due to the disproportionate growth of the elderly population. Globally, intensive care unit mortality in patients admitted with sCAP is about 30%.

In most sCAP patients, the blood clotting system is activated as part of the response to infection, in some cases interfering with circulation and leading to multiple organ failure. Researchers hope reducing this excess clottingthrough use of anticoagulants in individuals with sCAP may prevent organ failure.

Tifacoginacts by blocking activated tissue factor, an essential for clot formation. In aprior trial of sepsis patients, tifacogin had shown some benefit for patients in that trial who had CAP. Based on those results, Dr. Wunderink said researchers involved in this study, dubbed CAPTIVATE (Community-Acquired Pneumonia Tifacogin Intra-Venous Administration Trial for Efficacy), aimed to assess the efficacy and safety of tifacogin as adjunct therapy in sCAP.

"CAP remains the most common cause of death from infection," Dr. Wunderink said. "Anti-clotting therapies are sought to complement the antimicrobial treatment and supportive care measures that are currently used for sCAP patients."

In this study, researchers enrolled 2,138 sCAPpatients from 188 centers from 2005 to 2008, randomizing them to receive tifacogin or placebo intravenously for four days. Although two doses of tifacogin (0.025 mg/kg/h and 0.075 mg/kg/h) were initially included in the study, the higher dose was dropped early on when no benefit was demonstrated.

At the end of the study although tifacogin did show an effect on clotting measures in the blood, the researchers found mortality rates and the incidence of adverse events were similar in both the tifacogin and placebo groups.

Dr. Wunderink said the study's negative results could be due to several factors.

"The coagulation and inflammatory responses may have been irreversibly activated before tifacogin was administered, or specific processes that occur during CAP may have blunted the effect of the drug," he said. "However, the most logical explanation is that tissue factor activation, while important, may not be a critical step in the pathogenesis of sCAP mortality."

Although the study showed no benefit associated with the use of tifacogin in sCAP patients, Dr. Wunderink said it clearly demonstrates the need for additional research to improve sCAP mortality rates.

"CAPTIVATE represents the largest clinical trial of severe CAP performed to date," Dr. Wunderink said. "The design and execution of the study demonstrates that a more homogeneous population with a single source ofinfection, rather than a more generic sepsis population, can be defined, which will be of benefit for future studies.

"Although theprimary end-point was not achieved, this study demonstrates the persistent unmet need forfurther interventions to improve mortality of sCAP and the feasibility of those studies," he added.


Contact: Brian Kell
American Thoracic Society

Related medicine news :

1. New Anti-Clotting Drug May Work Better After Hip Replacement
2. Extended use of anti-clotting drug helps some bedridden patients
3. Tests to Measure Safety of Anti-Clotting Drugs of Limited Value
4. VCU Massey first to combine targeted agents to kill multiple myeloma cells
5. SNM applauds FDA advisory committee recommendation for approval of Alzheimers imaging agent
6. Study provides molecular rationale for combining targeted agents to treat breast cancer
7. Colorectal cancer patients with gene mutation show better response to cancer agent
8. Targeted agent shows promise for chronic lymphoid leukemia
9. Agent Orange exposure linked to Graves disease in Vietnam veterans, UB study finds
10. New Research Uncovers Elusive Target of Antifungal Agent
11. Compound enhances cancer-killing properties of agent in trials
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions announced ... User Group (MSDSLUG). Recognized as Microsoft’s official group for end users of Dynamics ... software users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates their ...
(Date:11/27/2015)... ... 2015 , ... The men and women on this list ... the country. They have overseen financial turnarounds, shown commitment to their community through ... as a whole through their advocacy and professional efforts. , Becker's Hospital Review ...
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think Thanksgiving, they also ... buy during the Black Friday and Cyber Monday massage chair sales to ... Internet high and low to find the best massage chair deals, they can see ...
(Date:11/26/2015)... ... 2015 , ... PRMA Plastic Surgery is updating their record books yet again ... free flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, says ... and it’s an honor to have served all of these women.” , PRMA is ...
(Date:11/25/2015)... OAK BROOK, Ill. (PRWEB) , ... November 25, ... ... sometimes larger and potentially more aggressive than those found on mammography, according to ... cases MRI findings of additional cancers not seen on mammography may necessitate a ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
(Date:11/25/2015)... MINNEAPOLIS , Nov. 25, 2015  ARKRAY ... care products, continues to provide evidence demonstrating the accuracy ... the World Congress on Insulin Resistance, Diabetes and Cardiovascular ... showed that both the Company,s GLUCOCARD ® 01 ... met high accuracy requirements. The ability to accurately measure ...
Breaking Medicine Technology: